Galmed Pharmaceuticals Ltd. (GLMD): Price and Financial Metrics


Galmed Pharmaceuticals Ltd. (GLMD): $0.56

0.06 (+11.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GLMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GLMD Stock Price Chart Interactive Chart >

Price chart for GLMD

GLMD Price/Volume Stats

Current price $0.56 52-week high $4.08
Prev. close $0.50 52-week low $0.50
Day low $0.50 Volume 152,900
Day high $0.56 Avg. volume 111,110
50-day MA $1.30 Dividend yield N/A
200-day MA $2.09 Market Cap 14.02M

Galmed Pharmaceuticals Ltd. (GLMD) Company Bio


Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company was founded in 2000 and is based in Tel Aviv, Israel.


GLMD Latest News Stream


Event/Time News Detail
Loading, please wait...

GLMD Latest Social Stream


Loading social stream, please wait...

View Full GLMD Social Stream

Latest GLMD News From Around the Web

Below are the latest news stories about Galmed Pharmaceuticals Ltd that investors may wish to consider to help them evaluate GLMD as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, trader!

William White on InvestorPlace | March 18, 2022

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office (USPTO) granted Galmed new patents related to the use of Aramchol for the treatment of fibrosis and for the treatment for modulating gut microbiota. An additional patent grant protects the low dose composition of Aramchol salt until June 8, 2036. With these latest pat

Yahoo | January 11, 2022

Galmed announces positive results of Phase 1 study of Amilo-5MER

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results of a Phase 1 clinical trial of Amilo-5MER in healthy volunteers that demonstrated an excellent safety profile and tolerability.

Yahoo | January 10, 2022

Analysts Are Bullish on Top Healthcare Stocks: ImmunoGen (IMGN), TG Therapeutics (TGTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoGen (IMGN – Research Report), TG Therapeutics (TGTX – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) with bullish sentiments. ImmunoGen (IMGN) In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoGen, with a price target of $12.00. The company's shares closed last Tuesday at $6.17. According to TipRanks.

Catie Powers on TipRanks | December 1, 2021

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and nine months ended September 30, 2021.

Yahoo | November 8, 2021

Read More 'GLMD' Stories Here

GLMD Price Returns

1-mo -63.87%
3-mo N/A
6-mo -77.95%
1-year -78.71%
3-year -91.36%
5-year -88.80%
YTD -69.23%
2021 -41.48%
2020 -46.19%
2019 -15.37%
2018 -25.36%
2017 160.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7047 seconds.